Wikia

Psychology Wiki

Changes: Remoxipride

Edit

Back to page

(New page: {{BioPsy}} {{drugbox | IUPAC_name = 3-Bromo-N-[ [(''2S'')-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide | image = Remoxipride.png | CAS_number = 117591-7...)
 
 
Line 29: Line 29:
   
 
== Clinical trials ==
 
== Clinical trials ==
Remoxipride is a selective [[Dopamine receptor|D2]] [[Receptor antagonist|antagonist]], with a relatively low effective dosage and low incidence of side effects relative to [[haloperidol]]. However, after its introduction in Europe, its use was correlated with incidence of [[aplastic anemia]] in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.
+
Remoxipride is a selective [[Dopamine receptor|D2]] [[Receptor antagonist|antagonist]], with a relatively low effective dosage and low incidence of side effects relative to [[haloperidol]]. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.
   
 
== External links ==
 
== External links ==

Latest revision as of 23:02, September 13, 2007

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)


Remoxipride
Remoxipride

3-Bromo-N-[ [(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide
IUPAC name
CAS number
117591-79-4
ATC code

N05AL04

PubChem
54477
DrugBank
[1]
Chemical formula
Molecular weight 371.27 g/mol
Bioavailability C16H23BrN2O3
Metabolism
Elimination half-life
Excretion
Pregnancy category
Legal status
Routes of administration


Remoxipride is a substituted benzamide which was a promising antipsychotic during clinical trials in the 1990s, but was removed due to possible side effects.

Clinical trials Edit

Remoxipride is a selective D2 antagonist, with a relatively low effective dosage and low incidence of side effects relative to haloperidol. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.

External links Edit

This page uses Creative Commons Licensed content from Wikipedia (view authors).

Around Wikia's network

Random Wiki